



## Financial Tear Sheet

### Corporate Profile

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA<sup>®</sup> ER, NUCYNTA<sup>®</sup>, Gralise<sup>®</sup>, Cambia<sup>®</sup>, Lazanda<sup>®</sup> and Zipsor<sup>®</sup>. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential. Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform<sup>®</sup>, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed's products:

**NUCYNTA<sup>®</sup> ER** (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

**NUCYNTA<sup>®</sup>** (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

**Gralise<sup>®</sup>** (gabapentin), a once-daily product for the management of postherpetic neuralgia,

**Cambia<sup>®</sup>** (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

**Lazanda<sup>®</sup>** (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

**Zipsor<sup>®</sup>** (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for [Gralise](#) and the black box warnings for [NUCYNTA ER](#), [NUCYNTA](#), [Cambia](#), [Lazanda](#) and [Zipsor](#).

### Stock Performance

#### DEPO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$6.67</b>
Change (%)	<b>▼ 0.16 (2.34%)</b>
Volume	876,298
52 Week Low	\$4.31
Market Cap	\$423,652,234
Rolling EPS	-1.63
PE Ratio	N/A
Shares Outstanding	63,516,077



Data as of 04/25/18 4:00 p.m. ET

## Recent Headlines

04/17/18

Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications

04/09/18

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04/02/18

Depomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific Officer

## Upcoming Events

05/08/18 1:00 p.m. CT

Depomed Annual Shareholder Meeting

## Ownership Summary

### TOP HOLDERS

	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	8,816,360	13.9	-128,636	12/31/17
Senvest Management, LLC	4,896,958	7.7	-708,147	12/31/17
Starboard Value LP	4,540,565	7.2	-154,705	04/05/18
The Vanguard Group, Inc.	4,150,419	6.5	215,538	12/31/17
Armistice Capital LLC	3,658,000	5.8	-994,000	12/31/17
Dimensional Fund Advisors, L.P.	2,842,947	4.5	521,838	12/31/17
Renaissance Technologies LLC	2,723,400	4.3	1,704,200	12/31/17
State Street Global Advisors (US)	1,948,154	3.1	-342,044	12/31/17
Millennium Management LLC	1,904,663	3.0	609,948	12/31/17
Connor, Clark & Lunn Investment Management Ltd.	1,169,756	1.8	837,722	12/31/17

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed